Validating chemoimmunotherapy in small-cell lung cancer
- PMID: 35576958
- DOI: 10.1016/S1470-2045(22)00288-1
Validating chemoimmunotherapy in small-cell lung cancer
Conflict of interest statement
ASM reports research funding from the United States National Cancer Institute (R21 CA251923), Department of Defense, Mark Foundation, Novartis, and Verily; honoraria to institution for participation in advisory boards from AbbVie, AstraZeneca, BeiGene, BMS, Genentech, and Janssen; travel support and honoraria from Shanghai Roche; and is a non-remunerated member of the Mesothelioma Applied Research Foundation Board of Directors. KERS declares no competing interests.
Comment on
-
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
